Artiva Biotherapeutics (ARTV) CEO Aslan Fred Sells 23,429 Shares

What Happened
Aslan Fred, Chief Executive Officer of Artiva Biotherapeutics (ARTV), sold 23,429 shares on September 8, 2026. The transaction was a sale (S) for total proceeds of $255,746. The filing shows the sale was executed under a Rule 10b5-1 plan.

Key Details

• Transaction date: 2026-09-08; Form filed: 2026-09-09.
• Quantity and price: 23,429 shares sold; weighted average sale price $10.9158; price range $10.72–$11.13.
• Reported proceeds: $255,746.
• Plan disclosure: Occurred pursuant to a Rule 10b5-1 trading plan adopted May 13, 2026 (Footnote F1).
• Price breakdown: Footnote F2 notes the weighted average and price range and that detailed per-price quantities will be provided on request.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Timeliness: Filed the day after the transaction; not indicated as late.

Context

• Sales under 10b5-1 plans are pre-arranged and often reflect scheduled liquidity rather than a change in insider view of the company. This was a sale (not a purchase), which is generally viewed as routine insider selling unless part of a broader pattern.
• No option exercises, grants, gifts, or tax-withholding events were reported in this transaction.